# Durvalumab

## Imfinzi inj 500mg/10mL

| TAH Drug Code      | [IIMF](https://www.tahsda.org.tw/drugs/hissearch.php?drug_code=IIMF)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                |
|:-------------------|:------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Indications        | Non–small cell lung cancer; Small cell lung cancer; Hepatocellular carcinoma， unresectable， combination therapy; Biliary tract cancer; Endometrial cancer                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         |
| Dosing             | Hepatocellular carcinoma， unresectable， combination therapy: Patients >=30 kg: IV: 1，500 mg on day 1 of cycle 1 (in combination with tremelimumab)， followed by 1，500 mg once every 4 weeks as a single agent; continue until disease progression or unacceptable toxicity. Patients <30 kg: IV: 20 mg/kg on day 1 of cycle 1 (in combination with tremelimumab)， followed by 20 mg/kg once every 4 weeks as a single agent; continue until disease progression or unacceptable toxicity. Endometrial cancer， advanced or recurrent， mismatch repair deficient (dMMR): Note: Select patients for therapy based on the presence of dMMR in tumor specimens. Patients ?30 kg: IV: 1，120 mg once every 3 weeks (in combination with carboplatin and paclitaxel) for 6 cycles， followed by 1，500 mg once every 4 weeks as a single agent; continue until disease progression or unacceptable toxicity. Patients <30 kg: IV: 15 mg/kg once every 3 weeks (in combination with carboplatin and paclitaxel) for 6 cycles， followed by 20 mg/kg once every 4 weeks as a single agent; continue until disease progression or unacceptable toxicity.                                                                                                                                                                              |
| Hepatic Impairment | Dose adjustment not necessary                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       |
| Renal Impairment   | Dose adjustment not necessary                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       |
| Contraindications  | Hypersensitivity to durvalumab or any component of the formulation.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 |
| Adverse Effects    | >10%: Dermatologic: Pruritus (12% to 13%)， skin rash (18% to 23%; including dermatitis， eczema， exfoliation of skin) Endocrine & metabolic: Hyperglycemia (52%)， hyperkalemia (23% to 32%)， hyperthyroidism (12%)， hypocalcemia (46%)， hyponatremia (32% to 33%)， hypothyroidism (12% to 17%) Gastrointestinal: Decreased appetite (17%)， diarrhea (11%; grades 3/4: 2%)， nausea (13%) Hematologic & oncologic: Lymphocytopenia (34% to 43%; grades 3/4: 10% to 17%) Hepatic: Increased gamma-glutamyl transferase (24% to 32%)， increased serum alanine aminotransferase (36% to 39%)， increased serum aspartate aminotransferase (33% to 36%) Nervous system: Dizziness (14%)， fatigue (21% to 34%; including asthenia) Renal: Increased serum creatinine (21%) Respiratory: Cough (<=40%)， dyspnea (11%)， pneumonia (13% to 17%)， pneumonitis (<=38%; including pulmonary fibrosis)， productive cough (<=40%)， radiation pneumonitis (<=38%; including interstitial lung disease)， upper respiratory tract infection (26%) Miscellaneous: Fever (15%) 1% to 10%: Cardiovascular: Peripheral edema (<10%) Dermatologic: Night sweats (<10%) Gastrointestinal: Abdominal pain (10%) Genitourinary: Dysuria (<10%) Infection: Increased susceptibility to infection (<10%) Nervous system: Voice disorder (<10%) |
| Pregnancy          | Unknown                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             |
| Lactation          | Unknown                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             |
| More Info          | [UpToDate](https://www.uptodate.com/contents/durvalumab-drug-information)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           |

